dopaminergic receptor agonist

From Aaushi
Jump to navigation Jump to search

Adverse effects

Drug interactions

More general terms

More specific terms

Additional terms

References

  1. Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 1051
  2. 2.0 2.1 Prescriber's Letter 9(3):17 2002
  3. 3.0 3.1 3.2 3.3 Medical Knowledge Self Assessment Program (MKSAP) 16 American College of Physicians, Philadelphia 2012
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  4. 4.0 4.1 Moore TJ et al Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs. JAMA Intern Med. Published online October 20, 2014. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25329919 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=1916909
    Gagne JJ Finding Meaningful Patterns in Adverse Drug Event Reports. JAMA Intern Med. Published online October 20, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25329621 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=1916906
    Weiss HD, Pontone GM Dopamine Receptor Agonist Drugs and Impulse Control Disorders. JAMA Intern Med. Published online October 20, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25329734 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=1916907
  5. 5.0 5.1 Corvol JC, Artaud F, Cormier-Dequaire F et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018 Jul 17;91(3):e189-e201. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29925549 <Internet> http://n.neurology.org/content/91/3/e189